FDA expands early breast cancer indication for abemaciclib with ...
WEBAbemaciclib is a CDK4/6 inhibitor that can be used with endocrine therapy for high-risk node-positive, HR-positive, HER2-negative breast cancer. The approval is based on a trial that showed...
Abemaciclib May Be Option for Early-Stage Breast Cancer
WEBJan 6, 2021 · A clinical trial suggests that abemaciclib, a CDK4/6 inhibitor, may reduce the risk of cancer recurrence in high-risk early-stage breast cancer. The drug is approved by FDA for advanced disease and requires a companion diagnostic test.
FDA approves abemaciclib with endocrine therapy for early breast …
WEBAbemaciclib is a CDK 4/6 inhibitor that can be combined with endocrine therapy for adjuvant treatment of high-risk, node-positive, HR-positive, HER2-negative breast cancer. The FDA also approved...
Switching to Abemaciclib May Improve Outcomes After Disease …
WEBJul 10, 2024 · Real-world evidence suggests that use of abemaciclib after disease progression on a prior CDK4/6 inhibitor may extend progression-free survival, although phase II trials with CDK4/6 inhibitors aside from abemaciclib have generated mixed results.
MonarchE Update: Benefit of Abemaciclib Increases Over Time
WEBDec 11, 2022 · Results of a planned interim overall survival analysis of the phase III monarchE trial offer further support for the addition of abemaciclib to adjuvant endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive, high-risk breast cancer, according to Stephen R.D. Johnston, MD, …
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone …
WEBJan 9, 2024 · Two years of adjuvant abemaciclib combined with endocrine therapy (ET) resulted in a significant improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) that persisted beyond the 2-year treatment period in patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative, node ...
Adding abemaciclib to treatment leads to longer time without
WEBA study found that adding abemaciclib to hormonal therapy improved invasive disease-free survival for people with high-risk, hormone receptor-positive early breast cancer. The results are promising but not yet final, and the medicine has …
Abemaciclib With ET Outperforms Chemotherapy in Advanced …
WEB4 days ago · In the abemaciclib plus ET arm, 65% of patients had an ECOG performance status of 0 compared with 63.4% in the paclitaxel arm. Further, 64% of patients had visceral disease present, 36% had 3 or more metastatic sites, and 36.2% in the abemaciclib plus ET arm and 28.1% in the paclitaxel arm had de novo advanced breast cancer.
WEBJan 27, 2022 · Abemaciclib is a kinase inhibitor that improves invasive disease-free survival in patients with hormone receptor-positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score of 20%. The FDA approval was based on the monarchE trial, which showed a statistically significant benefit in invasive disease-free survival but no clear benefit or harm in overall survival.
Elacestrant Plus Abemaciclib Demonstrates Clinical Benefit in ...
WEB1 day ago · Those in cohort 1 (n = 8) received elacestrant at 258 mg per day plus abemaciclib at 100 mg twice per day; patients in cohort 2 (n = 7) were given elacestrant at 345 mg once per day plus ...